Teva Pharmaceutical Industries Ltd. (TEVA) has finally appointed a new CEO named Kare Schultz. Shareholders seemed desperate enough that simply appointing any CEO would probably have been positively received. In this article, I will explore Schultz's previous roles as well as his previous achievements. According to my research, Teva Shareholders could not have wished for a better CEO.
Why the CEO is so important
Normally, dedicating a whole article to a CEO is really not worth it as there usually isn't much to say. This situation is different because the company has been deteriorating faster than previously thought. Followers will know that I was quite positive about Teva since Q1 2017. But given that Allergan (NYSE:AGN) owned 10% of the company and was --according to my analysis -- looking to offload those shares as soon as the lock up expired in August 2017, I cautioned against purchasing shares just yet. Instead, I stated that would-be shareholders were better off waiting until after August 2017:
